一种针对HPV16 E6 E7的治疗性多表位蛋白质疫苗引起了强大的瘤回归和细胞毒性免疫反应
Lanfang Zhu1, Jingtao Pu1,2, Yufen Tao1
1Department of Immunogenetics, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming 650118, China.
Cancer biology & medicine
|October 7, 2025
概括
一种新型蛋白质疫苗,Pro-HSP70-12P,有效地向人类乳头瘤病毒 (HPV) E6/E7coproteins,在临床前模型中诱导瘤回归和长期免疫力. 这种治疗性疫苗在治疗HPV驱动的癌症方面表现有前途.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
背景情况:
- 持续高风险的人类乳头瘤病毒 (hrHPV) 感染是宫癌死亡的主要原因.
- 针对HPVcoproteins的治疗性疫苗对于管理现有的感染和癌前病变至关重要.
研究的目的:
- 设计和评估一种针对HPV16 E6/E7coproteins的新型多表位疫苗.
- 为了增加治疗效果,将新发现的免疫主导表位物纳入.
主要方法:
- HSP70-12P疫苗的生物信息设计包含HPV16 E6/E7细胞毒性T淋巴细胞 (CTL) 和辅助T淋巴细胞 (HTL) 表位与Mycobacterium结核病HSP70辅助剂融合.
- 在TC-1瘤携带小鼠模型中评估基于蛋白质 (Pro-HSP70-12P) 和基于DNA (DNA-HSP70-12P) 的配方.
- 评估瘤回归,生存率,T细胞反应和细胞因子概况;通过ELISpot识别免疫主导表位.
主要成果:
- 蛋白质疫苗Pro-HSP70-12P诱导了强大的免疫反应,并提供了持续的抗瘤保护.
- 观察到显著的瘤清除,激活细胞介导免疫和效应记忆T细胞.
- 普罗-HSP70-12P的效果优于DNA疫苗,只需一剂量就能实现小瘤的完全回归,并提供长期的保护.
结论:
- Pro-HSP70-12P多表位蛋白疫苗是HPV驱动恶性瘤的强有力的治疗候选者.
- 该疫苗证明了瘤回归和诱导长期免疫力的能力.
- 这些发现支持PRO-HSP70-12P在HPV相关癌症的进一步临床开发.
相关概念视频
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
01:30Cancer Vaccines
960
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
960
01:27Cytotoxic T Cells-mediated Immune Response
6.5K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.5K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K